CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure. From Wikipedia
The acquisition aims to bolster Novo Nordisk's cardiovascular medicine portfolio, focusing on heart failure treatment CDR132L.
